Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Thrombocytopenia 1Neutropenia 1Neoplasms 1Genital Neoplasms, Female 1Colorectal Neoplasms 1Breast Neoplasms 1Anemia 1

Interventions

ferric carboxymaltose 5Epoetin Alfa 2venetoclax 1trametinib 1ruxolitinib 1regorafenib 1ponatinib 1pertuzumab 1pembrolizumab 1palbociclib 1olaparib 1neratinib 1lorlatinib 1lenvatinib 1iron isomaltoside 1000 1idelalisib 1ferrous sulfate 1ferrous fumarate 1enzalutamide 1entrectinib 1enasidenib 1durvalumab 1dehydroftorafur 1darolutamide 1dacomitinib 1dabrafenib 1copanlisib 1cobimetinib 1cabozantinib 1cabazitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anemia × Moxibustion × Gastrointestinal × Clear all
NCT02781155 2016-05-24

Limiting Chemotherapy Side Effects by Using Moxa

East and North Hertfordshire NHS Trust

Phase 1/2 Unknown
25 enrolled
BreastClassical hematologyGastrointestinal

Anemia, Breast Neoplasms, Genital Neoplasms, Female, Neoplasms, Neutropenia, Thrombocytopenia, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡